• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    4/16/24 8:07:06 AM ET
    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Dynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million.
    • BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.48% to $1.63. The market value of their outstanding shares is at $11.0 million.
    • Akanda (NASDAQ:AKAN) shares increased by 23.0% to $0.14. The company's market cap stands at $1.6 million.
    • Cullinan Oncology (NASDAQ:CGEM) shares moved upwards by 20.89% to $20.01. The company's market cap stands at $861.6 million.
    • Intra-Cellular Therapies (NASDAQ:ITCI) stock moved upwards by 18.85% to $76.97. The market value of their outstanding shares is at $7.4 billion.
    • Alzamend Neuro (NASDAQ:ALZN) shares moved upwards by 15.07% to $0.85. The market value of their outstanding shares is at $5.8 million.

    Losers

    • Inovio Pharmaceuticals (NASDAQ:INO) shares fell 24.3% to $8.32 during Tuesday's pre-market session. The company's market cap stands at $194.4 million.
    • Calidi Biotherapeutics (AMEX:CLDI) stock decreased by 22.5% to $0.47. The market value of their outstanding shares is at $16.5 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock decreased by 20.06% to $0.24. The market value of their outstanding shares is at $1.5 million.
    • Addex Therapeutics (NASDAQ:ADXN) shares declined by 12.69% to $21.61. The company's market cap stands at $22.8 million.
    • Poseida Therapeutics (NASDAQ:PSTX) shares fell 12.66% to $2.12. The market value of their outstanding shares is at $204.7 million.
    • Organovo Holdings (NASDAQ:ONVO) shares decreased by 10.38% to $1.21. The company's market cap stands at $12.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AKAN
    $ALZN
    $BRTX

    CompanyDatePrice TargetRatingAnalyst
    Cullinan Therapeutics Inc.
    $CGEM
    2/17/2026$33.00Buy
    Citigroup
    Cullinan Therapeutics Inc.
    $CGEM
    2/2/2026$30.00Buy
    Guggenheim
    Cullinan Therapeutics Inc.
    $CGEM
    8/21/2025$24.00Buy
    H.C. Wainwright
    Inovio Pharmaceuticals Inc.
    $INO
    7/9/2025$5.00Overweight
    Piper Sandler
    Cullinan Therapeutics Inc.
    $CGEM
    6/11/2025$22.00Buy
    Stifel
    Intra-Cellular Therapies Inc.
    $ITCI
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    Intra-Cellular Therapies Inc.
    $ITCI
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    Poseida Therapeutics Inc.
    $PSTX
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Cullinan Therapeutics with a new price target

    Citigroup initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $33.00

    2/17/26 8:16:46 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Cullinan Therapeutics with a new price target

    Guggenheim initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

    2/2/26 6:51:16 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Cullinan Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $24.00

    8/21/25 8:17:52 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Humeau Laurent converted options into 12,376 shares and covered exercise/tax liability with 5,098 shares, increasing direct ownership by 22% to 39,900 units (SEC Form 4)

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    2/27/26 4:49:03 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    CFO Kies Peter converted options into 15,644 shares and covered exercise/tax liability with 9,259 shares, increasing direct ownership by 21% to 36,642 units (SEC Form 4)

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    2/27/26 4:48:27 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Shea Jacqueline Elizabeth covered exercise/tax liability with 21,714 shares and converted options into 47,033 shares, increasing direct ownership by 42% to 85,004 units (SEC Form 4)

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    2/27/26 4:47:50 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

    Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancerNovel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute Study builds on the previously reported positive Phase II results involving INO-5401 in GBM, adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding.HONG KONG and PLY

    3/4/26 8:52:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

    Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum MELVILLE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today issued the following letter to shareholders from Chief Executive Officer Lance Alstodt: To our shareholders and stakeholders, The first quarter of 2026 marks a pivotal period for BioRestorative Therapies. We have achie

    3/4/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.

    SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    3/4/26 3:16:34 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Alzamend Neuro Inc.

    DEFA14A - Alzamend Neuro, Inc. (0001677077) (Filer)

    2/26/26 5:12:52 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/30/25 5:13:32 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/21/25 7:00:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Financials

    Live finance-specific insights

    View All

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro

    12/4/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

    Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025 Title:  Addex Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Upd

    12/1/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review grantedCommercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA Results from Phase 1 proof-of-concept trial evaluating INOVIO's next generation DNA-Encoded Monoclonal Antibody (DMAb™) technology published in Nature MedicinePLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help trea

    11/10/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $ADXN
    $AKAN
    $ALZN
    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 5:05:22 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care